References
- Centers for Disease Control and Prevention National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 Atlanta, GA US Department of Health and Human Services 2014
- Wysham CH New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals Postgrad Med 2010 122 52 60 20463414
- Turner RC Cull CA Frighi V Holman RR Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 1999 281 12 2005 2012 10359389
- Centers for Disease Control and Prevention (CDC) National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011 Atlanta, GA U.S. Department of Health and Human Services, Centers for Disease Control and Prevention 2011
- Inzucchi SE Bergenstal RM Buse JB Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 2012 55 1577 1596 22526604
- Divino V DeKoven M Hallinan S Glucagon-like peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries Diabetes Ther 2014 5 2 499 520 25366334
- Fineman MS Bicsak TA Shen LZ Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes Diabetes Care 2003 26 2370 2377 12882864
- Degn KB Juhl CB Sturis J One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 2004 53 1187 1194 15111485
- Kim D MacConell L Zhuang D Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 2007 30 1487 1493 17353504
- Bydureon [package insert] San Diego, CA Amylin Pharmaceuticals Inc 2012
- Victoza [package insert] Plainsboro, NJ Novo Nordisk 2013
- Bergenstal RM Wysham C MacConnel L Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 2013 376 431 439 20580422
- Hall GC McMahon AD Dain MP Wang E Home P Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK Diabet Med 2013 30 6 681 686 23330649
- Buse JB Nauck M Forst T Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized, open-label study Lancet 2013 381 9861 117 124 23141817
- Scott DA Boye KS Timlin L Clark JF Best JH A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo Diabetes Obes Metab 2013 15 3 213 23 22958381
- Inzucchi SE Bergenstal RM Buse JB American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 1364 1379 22517736
- Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 540 559 19858063